Juan Carden
Saint Louis, MONPI 1639101868
Payments from drug & device makers
$2,130in general payments, 2019–2025
Across 130 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$203
- Incyte Corporation$184
- Merck$163
- AstraZeneca$159
- Bristol Myers Squibb$155
- Sanofi$148
- plus $1K from 20 others
What the payments were for
- Food & beverage$1,96292%
- Education$1688%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
19
20
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 14 | $203 |
| Incyte Corporation | 6 | $184 |
| Merck | 9 | $163 |
| AstraZeneca(2 entities) | 9 | $159 |
| Bristol Myers Squibb | 10 | $155 |
| Sanofi | 9 | $148 |
| Genentech USA, Inc. | 13 | $129 |
| Johnson & Johnson | 6 | $120 |
| Pfizer | 8 | $118 |
| Amgen | 6 | $108 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $87 |
| Mylan Institutional Inc. | 5 | $69 |
| Gilead | 5 | $67 |
| Exelixis Inc. | 4 | $64 |
| Lilly USA, LLC | 4 | $62 |
| Bayer | 2 | $41 |
| Boehringer Ingelheim | 2 | $40 |
| Astellas Pharma US Inc | 2 | $38 |
| Puma Biotechnology, Inc. | 2 | $28 |
| Lexicon Pharmaceuticals, Inc. | 2 | $27 |
| Taiho Oncology, Inc. | 1 | $24 |
| AMAG Pharmaceuticals, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Verastem, Inc. | 1 | $21 |
| AbbVie | 1 | $19 |
| Dova Pharmaceuticals | 1 | $11 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.